Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pimitespib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pimitespib overview
Pimitespib (Jeselhy) belongs to a class of antineoplastic drugs. It is formulated as tablets for oral route of administration. Jeselhy is indicated for the treatment of gastrointestinal stromal tumor (GIST) that has progressed after chemotherapy.
Pimitespib (TAS-116) is under development for the treatment of solid tumors including HER2 negative breast cancer, small cell lung cancer, endometrial cancer, bladder cancer, gastrointestinal stromal tumor (GIST), prostate cancer and non-small cell lung carcinoma. It is a small molecule administered orally. It is a HSP90 inhibitor.
It was under development for gastric cancer,HER2+ breast cancer, thymic carcinoma, metastatic pancreatic cancer, metastatic biliary tract cancer, metastatic lung cancer and solid tumor
Otsuka Pharmaceutical overview
Otsuka Pharmaceutical (OPC), a subsidiary of Otsuka Holdings Co Ltd, is a manufacturer and supplier of pharmaceuticals, food products, clinical testing, and medical equipment. The company develops formulations for the diagnosis and treatment of central nervous system, oncology, cardiovascular and renal, gastrointestinal, ophthalmology disorders and infectious diseases through its pharmaceutical business. Its nutraceutical segment offers rehydration, nutrition, vitamin supplements and cosmetics. OPC is investigating drugs for psychiatry and neurology; oncology; cardiovascular and other therapeutic indications in collaboration with academia and venture companies. The company operates branch offices, research facilities and factories in Japan. OPC is headquartered in Chiyoda-ku, Tokyo, Japan.
For a complete picture of Pimitespib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
